Novo Nordisk

CHMP Recommends Expanding Novo Nordisk’s Alhemo® Access to Broader Haemophilia Population Without Inhibitors

(IN BRIEF) Novo Nordisk has received a positive opinion from the European Medicines Agency’s CHMP recommending label expansion for Alhemo®…

3 months ago

Novo Nordisk Revamps Executive Team: New Leadership Roles Set to Drive Global Strategy

(IN BRIEF) Effective 3 April 2025, Novo Nordisk will undergo key changes in its Executive Management. Camilla Sylvest, a long-time…

6 months ago

Evotec and Novo Nordisk Expand LAB eN² Program and Select First Projects to Advance Cardiometabolic Research

(IN BRIEF) Evotec and Novo Nordisk’s LAB eN² program, a translational drug discovery accelerator, has selected its first three academic…

10 months ago

Novo Nordisk Launches Global Childhood Obesity Initiative to Support Healthier Urban Communities

(IN BRIEF) Novo Nordisk has launched the Childhood Obesity Prevention Initiative, aimed at combating rising obesity rates among children in…

12 months ago

Patients as Partners® Europe Announces the Launch of 8th Annual Meeting with 2024 Keynotes and Topics

(IN BRIEF) The Conference Forum announced the launch of the 8th annual Patients as Partners® Europe meeting, scheduled for May…

2 years ago

Novo Nordisk Hosts Capital Markets Day to Share Progress on Strategic Aspirations 2025

(IN BRIEF) Novo Nordisk is conducting a Capital Markets Day (CMD) to provide updates on its Strategic Aspirations 2025. The…

2 years ago

Novo Nordisk’s Semaglutide Shows Promise in Kidney Outcomes Trial FLOW

(IN BRIEF) Novo Nordisk has announced promising headline results from the kidney outcomes trial FLOW, which compared injectable semaglutide 1.0…

2 years ago

Novo Nordisk Announces Annual General Meeting Date and Proposals for Board Re-election

(IN BRIEF) Novo Nordisk A/S has announced the date for its Annual General Meeting, scheduled for Thursday, March 21, 2024,…

2 years ago

Almirall Secures Global Rights for Promising Dermatological Treatment, NN-8828, Targeting IL-21

(IN BRIEF) Almirall S.A., a leading pharmaceutical company specializing in medical dermatology, has finalized an exclusive license agreement with Novo…

2 years ago

Novo Nordisk Initiates Groundbreaking Collaborations for Innovative Obesity and MASH Treatments

(IN BRIEF) Novo Nordisk has announced separate research collaborations with Omega Therapeutics and Cellarity Inc. to explore innovative treatment approaches…

2 years ago

Novo Nordisk’s SELECT Trial Shows Semaglutide 2.4 mg Cuts Cardiovascular Risk in Overweight and Obese Adults

(IN BRIEF) Novo Nordisk, a global healthcare company, has reported the headline findings from the SELECT cardiovascular outcomes trial. This…

2 years ago

Novo Nordisk’s Bid for BIOCORP Set at 35.00 Euros per Share, Totaling 154 Million Euros

(IN BRIEF) Novo Nordisk A/S is in exclusive negotiations to acquire a controlling stake in BIOCORP Production SA, a French…

2 years ago

Vereinbarung zur Herstellung von nachhaltigem E-Methanol, unterzeichnet von LEGO Group, Novo Nordisk und European Energy

(IN KÜRZE) Die LEGO Group und Novo Nordisk haben sich mit European Energy zusammengetan, um E-Methanol, eine kohlenstoffärmere Alternative zu…

2 years ago

Sustainable e-methanol production agreement signed by LEGO Group, Novo Nordisk, and European Energy

(IN BRIEF) The LEGO Group and Novo Nordisk have partnered with European Energy to use e-methanol, a lower-carbon alternative to…

2 years ago